Supernus Pharmaceuticals, Inc. (SUPN): Operating Cash Flow
$47.33M
Year ended 2025-12-31
$19.91M
Trailing 12 months to 2026-06-30
-26.0%
3-year compound annual growth
-19.3%
5-year compound annual growth
+3.2%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $47.33M | -72.5% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $171.95M | +54.8% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $111.08M | -4.9% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $116.83M | -8.1% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $127.13M | -8.1% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $138.40M | -3.3% | 2023-03-09, From 2020-01-01 |
| 2019-12-31 | $143.13M | +11.0% | 2022-04-13, From 2019-01-01 |
| 2018-12-31 | $128.99M | +12.5% | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | $114.64M | +71.6% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $66.81M | +93.5% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $34.52M | n/m | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | -$24.50M | n/m | 2017-01-20, From 2014-01-01 |
| 2013-12-31 | -$57.95M | n/m | 2017-01-20, From 2013-01-01 |
| 2012-12-31 | -$47.20M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$36.19M | n/m | 2014-03-21, From 2011-01-01 |
| 2010-12-31 | -$32.54M | n/a | 2013-03-15, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $47.33M | -72.5% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $156.12M | -26.8% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $151.99M | -19.7% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $170.60M | +190.6% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $142.00M | -28.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $137.99M | +437.1% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$466.00M | n/m |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $329.32M | +60.7% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$93.41M | n/m |
Compare SUPN, AMPH, PCRX, EBS side by side · Screen every company in Pharmaceutical Preparations ↗